Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qurs e Fishar is a traditional Unani herbal medication developed by Hamdard Laboratories (Waqf) Pakistan for the treatment of mild to moderate hypertension. The primary active component of the formulation is derived from *Rauwolfia serpentina* (Indian Snakeroot), which contains a variety of alkaloids, most notably reserpine. These alkaloids act as antihypertensive agents by depleting stores of catecholamines, such as norepinephrine, from peripheral sympathetic nerve endings and the central nervous system. This action is mediated through the irreversible inhibition of the vesicular monoamine transporter (VMAT), which prevents the storage of neurotransmitters in synaptic vesicles. The resulting reduction in sympathetic activity leads to a decrease in peripheral vascular resistance and heart rate. Qurs e Fishar is currently undergoing Phase III clinical trials in Pakistan to evaluate its safety and efficacy in hypertensive adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qurs e Fishar.